Value proposition

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.

Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.

It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

Microbiome, Biotech, Research, Clinical Trials, Cancer, Oncology, Immuno-oncology, IBD, Microbiology, Science, Pharma, Therapeutics, Cell Biology, and Bioinformatics